## Exhibit D

From: Akeel Mithani <

To: Lisa Schlesinger
CC: Scott Breakstone
Sent: 8/25/2017 4:38:15 PM

Subject: RE: QuintilesIMS | Turing Support Discussion

For the other companies that data is outside of US. Regardless we need to put a block on IMS. Find out who are the people giving them the data and put a block on them too. Later would be Anne's part but I want the IMS block figured out ASAP.

Secondly, have we confirmed Symphony and IMS are the same company? I need the block on Symphony too ASAP

Very Important

Thanks

## Akeel Mithani

Office

From: Lisa Schlesinger

Sent: Friday, August 25, 2017 3:12 PM

To: Akeel Mithani < Cc: Scott Breakstone <

Subject: FW: QuintilesIMS | Turing Support Discussion

Akeel,

Is this the data you currently are finding?

Notice the NDC other products still out there.

Attached below are the companies associated with the NDC.

NDC	Trade Name	Labeler Name
52054-0330	DARAPRIM	Amedra Pharmaceuticals LLC
00173-0201	DARAPRIM	GlaxoSmithKline LLC
00179-0090	DARAPRIM	KAISER FOUNDATION HOSPITALS
52125-0003	DARAPRIM	REMEDYREPACK INC.
69413-0330	Daraprim	Turing Pharmaceuticals LLC

Lisa Schlesinger

Mobile

From: Amish Puri

**Sent**: Friday, August 25, 2017 2:16 PM

To: Lisa Schlesinger < Subject: RE: QuintilesIMS | Turing Support Discussion

Hi Lisa,

Yes we looked at a few years. Here is a report by month for reference by NDC. Thanks, Amish Amish Puri Account Director, US Pre-Commercial/Emerging Pharma QuintilesIMS 100 IMS Drive Parsippany, NJ 07054 Mobile: www.quintilesims.com From: Lisa Schlesinger Sent: Friday, August 25, 2017 2:12 PM To: Amish Puri ◀ Subject: Re: QuintilesIMS | Turing Support Discussion When you presented to us the last block was a few Years back I believe? Lisa Sent from my iPhone On Aug 25, 2017, at 2:07 PM, Amish Puri < > wrote: Hi Lisa, Correct, Walgreens has not provided us any notification that they are blocking Daraprim so it should be part of the reporting. That said, it would still be a good idea to check with them in case they are blocking and did not notify us. Thanks, Amish Amish Puri Account Director, US Pre-Commercial/Emerging Pharma <image001.jpg> 100 IMS Drive Parsippany, NJ 07054 Mobile: www.quintilesims.com From: Lisa Schlesinger | Sent: Friday, August 25, 2017 12:16 PM To: Amish Puri ◀ Subject: RE: QuintilesIMS | Turing Support Discussion

Hi Amish, Can you confirm you have the Walgreens Specialty data for Daraprim? Also I recall there wasn't a block on the Daraprim data? Could you please confirm? Thank you, Lisa Schlesinger Mobile From: Amish Puri Sent: Wednesday, August 9, 2017 2:32 PM To: Heather Preston >; Scott Breakstone >; Lisa Schlesinger < Subject: RE: QuintilesIMS | Turing Support Discussion Hello Scott and Lisa, Hope you are both doing well today and thank you again for your time yesterday. Per our discussion, please find attached the following: I will follow up in the next few days on FIA pricing and how we can leverage the existing credit situation. Thanks! Amish Michael Smith Patrick Crutcher Edwin Urrutia Christopher Lau Amish Puri Account Director, US Pre-Commercial/Emerging Pharma <image003.jpg>

CONFIDENTIAL FTC-Vyera00117385

100 IMS Drive Parsippany, NJ 07054

Mobile:

## www.quintilesims.com

-----Original Appointment-----From: Heather Preston

Sent: Tuesday, July 25, 2017 1:56 PM

To: Heather Preston; Scott Breakstone; Lisa Schlesinger; Mitch DeKoven; Amish Puri

Subject: QuintilesIMS | Turing Support Discussion

When: Tuesday, August 08, 2017 11:00 AM-1:00 PM (UTC-05:00) Eastern Time (US & Canada).

Where: 600 Third Ave, NYC | 10th Floor (between 39th and 40th streets) | Dial-In Below

All-

For anyone joining via conference call, please reference the below credentials:

Dial-In: Access Code:

Thanks! Heather

NOTICE: This e-mail message (including any attachments) is a private communication and may contain confidential, privileged or proprietary information meant solely for the intended recipient. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication is prohibited and may be unlawful. Please notify the sender immediately by replying to this message, then delete the e-mail and any attachments from your system.

NOTICE: This e-mail message (including any attachments) is a private communication and may contain confidential, privileged or proprietary information meant solely for the intended recipient. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication is prohibited and may be unlawful. Please notify the sender immediately by replying to this message, then delete the e-mail and any attachments from your system

## Case 1:20-cv-00706-DLC Document 424-4 Filed 05/17/21 Page 6 of 6

information and is intended for the authorized recipient of the sender. If you are not the intended recipient, you are hereby notified that any use, disclosure, copying, or distribution of this message or any of the information included in it is unauthorized and strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail and permanently delete this message and its attachments, along with any copies thereof, from all locations received (e.g., computer, mobile device, etc.). Thank you.

\*